{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:20:28Z","timestamp":1783408828515,"version":"3.54.6"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,7]]},"DOI":"10.7759\/cureus.112191","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:03:56Z","timestamp":1783407836000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Alafenamide in Treatment-Naive Patients Living With Human Immunodeficiency Virus (HIV) With High Viral Load: A Retrospective Observational Study"],"prefix":"10.7759","author":[{"given":"Hazel","family":"\u00d6zt\u00fcrk Belik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcmeyra","family":"\u015eim\u015fek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Kazak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harun","family":"A\u011fca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Heper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferah","family":"Budak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haluk Barbaros","family":"Oral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halis","family":"Akal\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. (2024). Accessed. June 20 2026: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/hiv-clinical-guidelines-adult-and-adolescent-arv\/what-start-initial-combin...."},{"key":"ref2","unstructured":"Initial regimens. ART-na\u00efve adults. (2026). http:\/\/eacs.sanfordguide.com\/en\/eacs-hiv\/art\/eacs-initial-regimens-arv-naive-adults."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials","volume":"385","author":"Sax PE","year":"2015","unstructured":"Sax PE, Wohl D, Yin MT, et al.. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, Phase 3, non-inferiority trials. Lancet. 2015, 385:2606-15. 10.1016\/S0140-6736(15)60616-X","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001350","article-title":"Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for initial HIV-1 treatment: week 144 results","volume":"75","author":"Arribas JR","year":"2017","unstructured":"Arribas JR, Thompson M, Sax PE, et al.. Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for initial HIV-1 treatment: week 144 results. J Acquir Immune Defic Syndr. 2017, 75:211-8. 10.1097\/QAI.0000000000001350","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000940","article-title":"Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results","volume":"72","author":"Wohl D","year":"2016","unstructured":"Wohl D, Oka S, Clumeck N, et al.. Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr. 2016, 72:58-64. 10.1097\/QAI.0000000000000940","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref6","article-title":"Clinical experience of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) in real life practice: data from the Turkish HIV-TR cohort","volume":"20","author":"Korten V","year":"2019","unstructured":"Korten V, \u0130nan A, Akal\u0131n H, et al.. Clinical experience of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide (E\/C\/F\/TAF) in real life practice: data from the Turkish HIV-TR cohort. HIV Medicine. 2019, 20:58.","journal-title":"HIV Medicine"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/17.4.802","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","author":"Castro KG","year":"1992","unstructured":"Castro KG, Ward JW, Slutsker L, et al.. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992, 41:1-19. 10.1093\/clinids\/17.4.802","journal-title":"MMWR Recomm Rep"},{"key":"ref8","article-title":"WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children","author":"World Health Organization","year":"2007","unstructured":"World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunologic classification of HIV-related disease in adults and children. World Health Organization (ed): World Health Organization, Geneva, Switzerland; 2007. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/d8e73c9c-b0ff-4dfb-a7a7-0596d56c8260\/content."},{"key":"ref9","article-title":"The effectiveness of E\/C\/F\/TAF in treatment-naive (TN) or treatment experienced (TE) adult HIV-infected patients in a real-world settings, results from southern Turkey","author":"\u0130nan D","year":"2019","unstructured":"\u0130nan D, Candevir Ulu A, Sar\u0131g\u00fcl Y\u0131ld\u0131r\u0131m F, et al.. The effectiveness of E\/C\/F\/TAF in treatment-naive (TN) or treatment experienced (TE) adult HIV-infected patients in a real-world settings, results from southern Turkey. 17th European AIDS Conference, Basel. 2019,","journal-title":"17th European AIDS Conference, Basel"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420983692","article-title":"Efficacy and safety of co-formulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide in HIV-positive patients: real-world data","volume":"32","author":"Tabak F","year":"2021","unstructured":"Tabak F, Zerdali E, Altunta\u015f O, et al.. Efficacy and safety of co-formulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide in HIV-positive patients: real-world data. Int J STD AIDS. 2021, 32:562-9. 10.1177\/0956462420983692","journal-title":"Int J STD AIDS"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2531","article-title":"Impact of pre-therapy viral load on virological response to modern first-line HAART","volume":"18","author":"Santoro MM","year":"2013","unstructured":"Santoro MM, Armenia D, Alteri C, et al.. Impact of pre-therapy viral load on virological response to modern first-line HAART. Antivir Ther. 2013, 18:867-76. 10.3851\/IMP2531","journal-title":"Antivir Ther"},{"key":"ref12","article-title":"Why are baseline HIV RNA levels 100,000 copies\/mL or greater associated with mortality after the initiation of antiretroviral therapy?","volume":"38","author":"Wood E","year":"2005","unstructured":"Wood E, Hogg RS, Yip B, et al.. Why are baseline HIV RNA levels 100,000 copies\/mL or greater associated with mortality after the initiation of antiretroviral therapy?. J Acquir Immune Defic Syndr. 2005, 38:289-95.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199910010-00009","article-title":"Predictors of optimal virological response to potent antiretroviral therapy","volume":"13","author":"Powderly WG","year":"1999","unstructured":"Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999, 13:1873-80. 10.1097\/00002030-199910010-00009","journal-title":"AIDS"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2987","article-title":"Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies\/ml initiated on elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate","volume":"21","author":"Adams JL","year":"2016","unstructured":"Adams JL, Byrne D, Pepe R, Gray A, Baxter JD. Virological failure in two patients with HIV-1 RNA viral loads >1,000,000 copies\/ml initiated on elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate. Antivir Ther. 2016, 21:175-80. 10.3851\/IMP2987","journal-title":"Antivir Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2018.03.012","article-title":"Rare emergence of drug resistance in HIV-1 treatment-na\u00efve patients receiving elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide for 144 weeks","volume":"103","author":"Margot N","year":"2018","unstructured":"Margot N, Cox S, Das M, McCallister S, Miller MD, Callebaut C. Rare emergence of drug resistance in HIV-1 treatment-na\u00efve patients receiving elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide for 144 weeks. J Clin Virol. 2018, 103:37-42. 10.1016\/j.jcv.2018.03.012","journal-title":"J Clin Virol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3187","article-title":"Virological outcomes of EVG\/COBI\/FTC\/TDF and EVG\/COBI\/FTC\/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA \u22651,000,000 copies\/ml: a post hoc analysis of Phase III clinical trials","volume":"23","author":"Sax P","year":"2018","unstructured":"Sax P, DeJesus E, Wohl D, et al.. Virological outcomes of EVG\/COBI\/FTC\/TDF and EVG\/COBI\/FTC\/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA \u22651,000,000 copies\/ml: a post hoc analysis of Phase III clinical trials. Antivir Ther. 2018, 23:95-9. 10.3851\/IMP3187","journal-title":"Antivir Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik KJ","year":"2017","unstructured":"Lepik KJ, Harrigan PR, Yip B, et al.. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS. 2017, 31:1425-34. 10.1097\/QAD.0000000000001494","journal-title":"AIDS"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1080\/09540120600839280","article-title":"Delayed access to HIV diagnosis and care: special concerns for the Southern United States","volume":"18 Suppl 1","author":"Krawczyk CS","year":"2006","unstructured":"Krawczyk CS, Funkhouser E, Kilby JM, Vermund SH. Delayed access to HIV diagnosis and care: special concerns for the Southern United States. AIDS Care. 2006, 18 Suppl 1:S35-44. 10.1080\/09540120600839280","journal-title":"AIDS Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/464885-evaluation-of-elvitegravircobicistatemtricitabinetenofovir-alafenamide-in-treatment-naive-patients-living-with-human-immunodeficiency-virus-hiv-with-high-viral-load-a-retrospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T07:04:12Z","timestamp":1783407852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/464885-evaluation-of-elvitegravircobicistatemtricitabinetenofovir-alafenamide-in-treatment-naive-patients-living-with-human-immunodeficiency-virus-hiv-with-high-viral-load-a-retrospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.112191","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}